You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Applied BioCode's test may be performed by any CLIA-certified lab, while Kaiser Permanente's and Emory's must be run at their developers' labs.
The firm said its panel, which runs on its MDx-3000 system, tests nasopharyngeal swabs for the most common viruses and bacteria.
The test detects 20 common viruses and bacteria that cause upper respiratory infections using the firm's high-throughput, automated MDx-3000 instrument.
Applied BioCode said that it now has access to higher volume laboratories that use the Roche MagNa Pure 96 System for sample extraction.
The firm will use the funds to commercialize its newly cleared molecular diagnostics platform and gastrointestinal pathogen panel test.
The BioCode GPP tests for 17 of the most common bacteria, viruses, and parasites that cause infectious diarrhea, and runs on the BioCode MDx-3000 system.
The company submitted the platform and gastrointestinal panel to the US Food and Drug Administration for clearance earlier this year.
The Gastrointestinal Pathogen Panel is the first of a number of planned infectious disease syndromic panels on the firm's PCR-based system.
Applied Biocode intends to have panel for identifying 18 gastrointestinal pathogens on the clinical market by the end of the year.
The companies will use their respective technologies to develop multiplex molecular diagnostic panels for laboratory testing.
Bloomberg reports the US Centers for Medicare & Medicaid Services sent Orig3n a letter saying it has not corrected lab issues uncovered in an earlier inspection.
In an editorial at BMJ Opinion, two genetic counselors call for an increased focus on post-test patient care.
A new survey finds people in the US are getting their COVID-19 test results back faster, but not fast enough to help some viral control measures, NPR reports.
In PLOS this week: genomic analysis of malaria parasites in Ethiopia, loci linked to childhood BMI, and more.